Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib + Fulvestrant in HR+/HER2- Breast Cancer
NCT04305496Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of capivasertib in breast cancer, sponsored by AstraZeneca. Started Apr 2020; status: active, not recruiting.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04305496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305496.